Vorapaxar 2.5 mg + Vorapaxar 1 mg + Placebo + Aspirin 75-150 mg
Phase 2Completed 0 watching 0 views this week⚡ Active
52
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Cerebral Infarction
Conditions
Cerebral Infarction
Trial Timeline
Sep 21, 2006 → Nov 8, 2007
NCT ID
NCT00684515About Vorapaxar 2.5 mg + Vorapaxar 1 mg + Placebo + Aspirin 75-150 mg
Vorapaxar 2.5 mg + Vorapaxar 1 mg + Placebo + Aspirin 75-150 mg is a phase 2 stage product being developed by Merck for Cerebral Infarction. The current trial status is completed. This product is registered under clinical trial identifier NCT00684515. Target conditions include Cerebral Infarction.
Hype Score Breakdown
Clinical
17
Activity
12
Company
10
Novelty
5
Community
5
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00684515 | Phase 2 | Completed |
Competing Products
20 competing products in Cerebral Infarction
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| mouse nerve growth factor | Sun Pharmaceutical | Approved | 85 |
| Edaravone Dexborneol + Placebo | Sun Pharmaceutical | Phase 2 | 52 |
| Oral Glycopyrrolate Liquid | Shionogi | Phase 3 | 77 |
| recombinant human erythropoietin alfa + 0.9% NaCl | Johnson & Johnson | Phase 2/3 | 65 |
| UDI-001 | Rohto Pharmaceutical | Phase 1/2 | 41 |
| NXY-059 | AstraZeneca | Phase 3 | 77 |
| NXY-059 | AstraZeneca | Phase 2 | 52 |
| Rosuvastatin | AstraZeneca | Approved | 85 |
| NXY-059 | AstraZeneca | Phase 3 | 77 |
| Comparator: Placebo + Comparator: MK0724 | Merck | Phase 2 | 52 |
| Recombinant Factor VIIa + Biological/Vaccine: Placebo | Novo Nordisk | Phase 3 | 76 |
| Recombinant Activated Factor VII (rFVIIa) + Placebo | Novo Nordisk | Phase 3 | 76 |
| Ponezumab | Pfizer | Phase 2 | 51 |
| PF-05230907 | Pfizer | Phase 1 | 32 |
| Azithromycin + Pyrimethamine + Leucovorin calcium | Pfizer | Phase 1 | 32 |
| clopidogrel (SR25990C) | Sanofi | Approved | 84 |
| Intrarectal quinine | Sanofi | Phase 3 | 76 |
| Piracetam | UCB | Approved | 82 |
| Placebo + ALN-APP | Alnylam Pharmaceuticals | Phase 2 | 49 |
| CN-105 | Tiantan Bio | Phase 2 | 49 |